seventy-five breast cancer patients scheduled to receive a first course ( in a new cycle ) of cyclophosphamide , fluorouracil , and doxorubicin ( fac ) or epirubicin ( fec ) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron ( gr38032 ) , a 5-hydroxytryptamine3 ( 5-ht3 ) receptor antagonist , and metoclopramide .
C0013089
doxorubicin
C0014582
epirubicin